Breast cancer-associated antigens (BCAA)

Breast cancer-associated antigens (BCAAs) represent a heterogeneous group of proteins, glycoproteins, and other molecules that are either uniquely expressed or significantly overexpressed in breast cancer cells compared to normal tissues [3, 7]. This broad category includes well-established therapeutic targets and diagnostic biomarkers such as Human Epidermal Growth Factor Receptor 2 (HER2), Mucin 1 (MUC1), and various oncofetal antigens like Carcinoembryonic Antigen (CEA) [3, 4]. These antigens play diverse roles in tumor biology, including promoting cell proliferation, survival, and metastasis, while also serving as focal points for the development of targeted therapies [2, 14]. Clinically, they are essential for subtyping breast cancer (e.g., HER2-positive vs. triple-negative), guiding treatment decisions, and monitoring disease progression or recurrence through serum assays [7, 17]. Therapeutic strategies targeting these antigens include monoclonal antibodies, antibody-drug conjugates (ADCs), and cancer vaccines designed to elicit a specific immune response against malignant cells [4, 5, 9]. The identification and characterization of novel BCAAs continue to be a major focus of research to overcome resistance and improve outcomes for patients with aggressive subtypes like triple-negative breast cancer [6, 13].

Other names

Tumor-associated antigensBreast cancer markersBreast cancer-associated antigen 1 (BRCAA1)Mucin 1 (MUC1)Human epidermal growth factor receptor 2 (HER2)Carcinoembryonic antigen (CEA)Cancer antigen 15-3 (CA 15-3)NY-BR-1MammaglobinSGA-72M

Inhibition of oncogenic signaling pathways (e.g., HER2/ERBB2), induction of antibody-dependent cellular cytotoxicity (ADCC), and targeted delivery of cytotoxic payloads via antibody-drug conjugates (ADCs) [4, 5, 7].